Table 2.

Agreement between lipid-lowering medication use in REGARDS and Medicare claims.

	No LLM in REGARDS		LLM in REGARDS
	No LLM in Medicare claims* N (%)†	LLM in Medicare claims* N (%)†	No LLM in Medicare claims* N (%)†	LLM in Medicare claims* N (%)†	Agreement % (95% CI)	Kappa (95% CI)
REGARDS medication inventory vs Medicare claims
Any LLM class	473 (52.6)	50 (5.6)	71 (7.9)	305 (33.9)	86.5 (84.1–88.7)	0.72 (0.68–0.77)
Statins	506 (56.3)	51 (5.7)	61 (6.8)	281 (31.3)	87.5 (85.2–89.6)	0.73 (0.69–0.78)
Branded statins‡	759 (84.4)	21 (2.3)	28 (3.1)	91 (10.1)	94.6 (92.9–95.9)	0.76 (0.69–0.82)
Generic statins‡	640 (71.2)	36 (4.0)	34 (3.8)	189 (21.0)	92.2 (90.3–93.9)	0.79 (0.75–0.84)
REGARDS self-report vs Medicare claims
Any LLM class	462 (51.4)	53 (5.9)	85 (9.4)	299 (33.3)	84.7 (82.1–86.9)	0.68 (0.63–0.73)
Both REGARDS self-report and medication inventory vs Medicare claims§
Any LLM class	367 (55.1)	65 (9.8)	37 (5.6)	197 (29.6)	84.7 (81.7–87.3)	0.67 (0.62–0.73)

CATI: computer-assisted telephone interview; CI: confidence intervals; LLM: lipid-lowering medication; REGARDS: REasons for Geographic And Racial Differences in Stroke.

^*Within 120 days prior the in-home visit for comparison with the REGARDS medication inventory and both self-report and medication inventory in REGARDS. Within 120 days prior the CATI for comparison with REGARDS self-report.

^†Row percentages.

^‡Branded statins included atorvastatin, rosuvastatin and fluvastatin. Generic statins included simvastatin, pravastatin and lovastatin.

^§For this analysis, LLM use in REGARDS was defined by both having a LLM in the medication inventory and self-reporting taking a LLM during the CATI.

Participants who reported taking LLM but did not have a LLM in their medication inventory or had a LLM in their medication inventory but did not self-report taking LLM were included in the “No LLM in REGARDS” category. This analysis was limited to participants who completed the REGARDS CATI and medication inventory within 45 days (n=666).